Journal Article Review Epublish 2 citations
PubMed: 40103829 DOI: 10.3389/fimmu.2025.1490491
CD19 -targeted CAR T therapy treating hematologic malignancies: hidden danger is the next neighbor to security?
Front Immunol 16:1490491
Authors: Xueshuai Ye, Min Ge, Mengtian Tan, Yongqiang Wu, Haiqiang Zhang, Zexian Fu
Affiliations
- Affiliated Hospital of Hebei Engineering University and School of Clinical Medicine, Hebei University of Engineering, Handan, China.
- Gene Editing Research Center, Hebei University of Science and Technology, Shijiazhuang, China.
- Department of Gastrointestinal Surgery, The Second Hospital of Hebei Medical University, Shijiazhuang, China.
- Medical College, Hebei University of Engineering, Handan, China.
Abstract
CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has achieved marvelous results in the treatment of patients with relapsed and/or refractory B-cell lymphomas, B-cell acute lymphoblastic leukemia, and multiple myeloma. As a new treatment method that has changed the existing treatment paradigm, there has been a short time from its emergence to FDA approval. However, with the increasing number of cases and the passage of time, hidden problems have gradually been exposed. In this review, we summarize the short- and long-term toxicity, such as secondary T-cell tumors and lethal CAR tumors, of patients with hematologic malignancies treated with CD19-CAR-T cells, including cytokine release syndrome (CRS), ICANS, and secondary malignancies with low occurrence rates but high mortality, such as secondary T cell tumors and lethal CAR tumors, which may be related to the gene modification mechanism of viral vectors currently approved for CAR-T cells. We also discuss potential investigational strategies designed to improve the safety of CAR-T-cell therapy.
MeSH
Cells, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, B-Cell, Hematologic Neoplasms, Neoplasms, Immune System Diseases, Therapeutics, Car-T Cell